vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and American Homes 4 Rent (AMH). Click either name above to swap in a different company.
American Homes 4 Rent is the larger business by last-quarter revenue ($455.0M vs $284.0M, roughly 1.6× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 31.7%, a 64.6% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 4.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 3.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
ACAD vs AMH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $455.0M |
| Net Profit | $273.6M | $144.3M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 31.7% |
| Revenue YoY | 9.4% | 4.2% |
| Net Profit YoY | 90.3% | 0.3% |
| EPS (diluted) | $1.61 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $455.0M | ||
| Q3 25 | $278.6M | $478.5M | ||
| Q2 25 | $264.6M | $457.5M | ||
| Q1 25 | $244.3M | $459.3M | ||
| Q4 24 | $259.6M | $436.6M | ||
| Q3 24 | $250.4M | $445.1M | ||
| Q2 24 | $242.0M | $423.5M | ||
| Q1 24 | $205.8M | $423.6M |
| Q4 25 | $273.6M | $144.3M | ||
| Q3 25 | $71.8M | $116.8M | ||
| Q2 25 | $26.7M | $123.6M | ||
| Q1 25 | $19.0M | $128.7M | ||
| Q4 24 | $143.7M | $143.9M | ||
| Q3 24 | $32.8M | $87.6M | ||
| Q2 24 | $33.4M | $108.5M | ||
| Q1 24 | $16.6M | $128.1M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | 31.7% | ||
| Q3 25 | 25.8% | 24.4% | ||
| Q2 25 | 10.1% | 27.0% | ||
| Q1 25 | 7.8% | 28.0% | ||
| Q4 24 | 55.4% | 33.0% | ||
| Q3 24 | 13.1% | 19.7% | ||
| Q2 24 | 13.8% | 25.6% | ||
| Q1 24 | 8.0% | 30.2% |
| Q4 25 | $1.61 | $0.33 | ||
| Q3 25 | $0.42 | $0.27 | ||
| Q2 25 | $0.16 | $0.28 | ||
| Q1 25 | $0.11 | $0.30 | ||
| Q4 24 | $0.86 | $0.33 | ||
| Q3 24 | $0.20 | $0.20 | ||
| Q2 24 | $0.20 | $0.25 | ||
| Q1 24 | $0.10 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $108.5M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $1.2B | $7.0B |
| Total Assets | $1.6B | $13.2B |
| Debt / EquityLower = less leverage | — | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $108.5M | ||
| Q3 25 | $258.0M | $45.6M | ||
| Q2 25 | $253.6M | $323.3M | ||
| Q1 25 | $217.7M | $69.7M | ||
| Q4 24 | $319.6M | $199.4M | ||
| Q3 24 | $155.1M | $162.5M | ||
| Q2 24 | $177.1M | $718.4M | ||
| Q1 24 | $204.7M | $124.8M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.2B | ||
| Q1 25 | — | $4.9B | ||
| Q4 24 | — | $5.0B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $1.2B | $7.0B | ||
| Q3 25 | $917.3M | $7.2B | ||
| Q2 25 | $822.4M | $7.2B | ||
| Q1 25 | $765.2M | $7.2B | ||
| Q4 24 | $732.8M | $7.2B | ||
| Q3 24 | $577.2M | $7.0B | ||
| Q2 24 | $516.7M | $7.0B | ||
| Q1 24 | $464.0M | $7.0B |
| Q4 25 | $1.6B | $13.2B | ||
| Q3 25 | $1.3B | $13.3B | ||
| Q2 25 | $1.2B | $13.6B | ||
| Q1 25 | $1.1B | $13.3B | ||
| Q4 24 | $1.2B | $13.4B | ||
| Q3 24 | $976.9M | $12.8B | ||
| Q2 24 | $914.1M | $13.3B | ||
| Q1 24 | $855.1M | $12.8B |
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.71× | ||
| Q1 24 | — | 0.64× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $864.3M |
| Free Cash FlowOCF − Capex | — | $823.7M |
| FCF MarginFCF / Revenue | — | 181.0% |
| Capex IntensityCapex / Revenue | — | 8.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 5.99× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $864.3M | ||
| Q3 25 | $74.3M | $223.3M | ||
| Q2 25 | $64.0M | $271.9M | ||
| Q1 25 | $20.3M | $223.4M | ||
| Q4 24 | $40.4M | $811.5M | ||
| Q3 24 | $63.2M | $233.6M | ||
| Q2 24 | $25.0M | $274.0M | ||
| Q1 24 | $29.1M | $201.8M |
| Q4 25 | — | $823.7M | ||
| Q3 25 | $73.9M | $214.5M | ||
| Q2 25 | — | $257.7M | ||
| Q1 25 | — | $215.9M | ||
| Q4 24 | — | $777.5M | ||
| Q3 24 | $63.2M | $225.3M | ||
| Q2 24 | — | $263.3M | ||
| Q1 24 | — | $191.0M |
| Q4 25 | — | 181.0% | ||
| Q3 25 | 26.5% | 44.8% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 47.0% | ||
| Q4 24 | — | 178.1% | ||
| Q3 24 | 25.2% | 50.6% | ||
| Q2 24 | — | 62.2% | ||
| Q1 24 | — | 45.1% |
| Q4 25 | — | 8.9% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | -0.18× | 5.99× | ||
| Q3 25 | 1.03× | 1.91× | ||
| Q2 25 | 2.40× | 2.20× | ||
| Q1 25 | 1.07× | 1.74× | ||
| Q4 24 | 0.28× | 5.64× | ||
| Q3 24 | 1.93× | 2.67× | ||
| Q2 24 | 0.75× | 2.52× | ||
| Q1 24 | 1.76× | 1.58× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
AMH
Segment breakdown not available.
